In vivo activity of cefbuperazone (T-1982) against various experimental infections in mice.
The protective activity of cefbuperazone (T-1982) was compared with those of latamoxef, cefotaxime, and cefmetazole against intraperitoneal and urinary tract infections in mice. In both tests, cefbuperazone manifested a higher activity than the other cephems against infections with Escherichia coli and Klebsiella pneumoniae. Cefbuperazone also showed a comparatively high degree of prophylactic effect; this activity was observed even when given 4 hours before bacterial challenge. The good in vivo activity of cefbuperazone could not be explained by the differences between the antibiotics on the basis of the serum levels and vitro activity. Mice, treated with cefbuperazone, showed a statistically significant prolongation of survival time against intraperitoneal challenge with Candida albicans, but not when treated with the other cephems. This finding suggests that the host defense mechanisms stimulated by cefbuperazone may contribute to the good in vivo activity of this antibiotic.
D000818:Animals; D001424:Bacterial Infections / Q000188:drug therapy*; D001770:Blood Bactericidal Activity; D002513:Cephamycins / Q000008:administration & dosage* / Q000097:blood; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D066298:In Vitro Techniques; D051379:Mice; D008826:Microbial Sensitivity Tests; D010529:Peritoneal Cavity / Q000382:microbiology; D014552:Urinary Tract Infections / Q000188:drug therapy*
D002513:Cephamycins; C035978:cefbuperazone